Novartis’ Promacta approved by FDA for first-line treatment of severe aplastic anemia

The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Novartis’ Promacta (eltrombopag), approving it for use in the first-line treatment of ... Read More